Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 20.28 0.17 (0.85%) Market Cap: 1.72 Bil Enterprise Value: 1.28 Bil PE Ratio: 0 PB Ratio: 3.50 GF Score: 53/100

Syndax Pharmaceuticals Inc at Cowen Oncology Innovation Summit: Insights for ASCO & EHA (Virtual) Transcript

Jun 02, 2022 / 04:30PM GMT
Release Date Price: $16.6 (+0.18%)
Phil Nadeau
Cowen and Company, LLC - Analyst

Good afternoon and welcome once again to Cowen and Company's Third Annual Oncology Innovation Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowen. And it's my pleasure to moderate a fireside discussion with Syndax Pharmaceuticals. We have with us today Michael Metzger, the Chief Executive Officer; and Anjali Ganguli, the Chief Business Officer.

And with that, we'll dive right into questions.

Questions & Answers

Phil Nadeau
Cowen and Company, LLC - Analyst

Most investor focus is on revumenib or SNDX-5613. Michael, could you give a brief summary of the efficacy data that were presented at ASH 2021 from AUGMENT-101 for those who are less familiar?

Michael Metzger
Syndax Pharmaceuticals, Inc. - CEO & Director

Sure. Pleasure to be here today. Phil. Thanks for having us and happy to summarize the data for you. So at ASH last December, we shared data from the Phase 1 portion of AUGMENT-101 testing revumenib, which is our menin inhibitor

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot